Mayne Pharma Group Limited
Symbol: MYX.AX
ASX
6.8
AUDMarktpreis heute
-2.3865
P/E-Verhältnis
-0.0091
PEG-Verhältnis
578.51M
MRK Kapital
- 0.00%
DIV Rendite
Mayne Pharma Group Limited (MYX-AX) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 229.2 | 97.1 | 98.4 | |||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 127.5 | 1.3 | 0 | |||||||||||||||||
balance-sheet.row.net-receivables | 0 | 209.5 | 283 | 193.3 | |||||||||||||||||
balance-sheet.row.inventory | 0 | 82.7 | 108.9 | 102.5 | |||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 32.2 | 22.6 | 22.3 | |||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 553.6 | 511.6 | 416.5 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 51.5 | 225.9 | 221.6 | |||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 22.1 | 20.3 | |||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 617.3 | 427.5 | 636.2 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 617.3 | 449.6 | 656.5 | |||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | -22.1 | -20.3 | |||||||||||||||||
balance-sheet.row.tax-assets | 0 | 23.4 | 133.7 | 187.2 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2.3 | 4.5 | 16.7 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 694.5 | 791.5 | 1061.6 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 0 | 1248.1 | 1303.1 | 1478.1 | |||||||||||||||||
balance-sheet.row.account-payables | 0 | 32 | 63.6 | 42.4 | |||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 14.4 | 408 | 54 | |||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 1.2 | 0 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 28.5 | 5.7 | 285.8 | |||||||||||||||||
Deferred Revenue Non Current | 0 | 4.6 | 0 | 7 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 256.9 | 156.9 | 125.9 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 302.8 | 135.6 | 484 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 4.6 | 5.7 | 7 | |||||||||||||||||
balance-sheet.row.total-liab | 0 | 613.8 | 764.9 | 706.6 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 0 | 1233.7 | 1238.5 | 1238.5 | |||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -769.8 | -840.3 | -559.1 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 170.4 | 147.7 | 88.9 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 634.4 | 545.9 | 768.4 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1248.1 | 1303.1 | 1478.1 | |||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | -7.7 | 3.2 | |||||||||||||||||
balance-sheet.row.total-equity | 0 | 634.4 | 538.2 | 771.6 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||
Total Investments | 0 | 127.5 | 1.3 | -20.3 | |||||||||||||||||
balance-sheet.row.total-debt | 0 | 47.5 | 413.7 | 346.8 | |||||||||||||||||
balance-sheet.row.net-debt | 0 | -54.2 | 316.6 | 248.5 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -317.4 | -209.5 | -208.4 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 65.4 | 55.2 | 68.2 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 50 | 63.4 | -43.9 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 6.8 | 4.6 | 7.7 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 145.4 | -8.9 | -13.6 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 118.7 | -66.1 | -3.2 | |||||||||||||||||
cash-flows.row.inventory | 0 | -12.1 | -2.4 | -25.9 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 45.3 | 60.7 | 16.4 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | -6.5 | -1.1 | -0.9 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 6.6 | 78.6 | 237.3 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -219.6 | -11.9 | -25.1 | |||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 842.2 | 5.2 | 0 | |||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -127.5 | 0 | 0 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-investing-activites | 0 | -21.6 | -21.8 | -24.1 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 473.5 | -28.5 | -49.2 | |||||||||||||||||
cash-flows.row.debt-repayment | 0 | -376 | -39.8 | -25.8 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 2.3 | 0 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -6.2 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | 0 | -45.3 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -6.2 | 76.8 | -3 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -431.5 | 37 | -28.8 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2.9 | 6.8 | -9 | |||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 4.6 | -1.3 | -39.8 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 101.7 | 97.1 | 98.4 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 97.1 | 98.4 | 138.2 | |||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -43.1 | -16.6 | 47.3 | |||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -219.6 | -11.9 | -25.1 | |||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -262.7 | -28.5 | 22.2 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 183.6 | 157.1 | 400.8 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 156.7 | 133.4 | 273.8 | |||||||||||||||||
income-statement-row.row.gross-profit | 0 | 26.8 | 23.7 | 127 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 0 | 12.6 | 74.4 | 6.4 | |||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 213.3 | 145.6 | 125.7 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 370 | 279 | 399.4 | |||||||||||||||||
income-statement-row.row.interest-income | 0 | 6.7 | 0.5 | 0.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 10.5 | 11.5 | 13.3 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -83.3 | -23.7 | -265.3 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 12.6 | 74.4 | 6.4 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -83.3 | -23.7 | -265.3 | |||||||||||||||||
income-statement-row.row.interest-expense | 0 | 10.5 | 11.5 | 13.3 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 65.4 | 55.2 | 68.2 | |||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | 0 | -186.4 | -121.9 | 1.4 | |||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -269.7 | -145.6 | -263.9 | |||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 47.7 | 74.5 | -54.8 | |||||||||||||||||
income-statement-row.row.net-income | 0 | -316.4 | -281.3 | -208.4 |
Häufig gestellte Frage
Wie hoch ist die Mayne Pharma Group Limited (MYX.AX) Gesamtvermögen?
Mayne Pharma Group Limited (MYX.AX) Gesamtvermögen ist 1248134000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.437.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.359.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -0.897.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.381.
Was ist der Mayne Pharma Group Limited (MYX.AX) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -316419000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 47505000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 213282000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.